Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514001 · ClinicalTrials.gov registry record · Phase 2
A Study of AMDX-2011P in Participants With Alzheimer's Disease
A Phase 2 study of Alzheimer Disease, sponsored by Amydis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06514001 is a Phase 2 study of Alzheimer Disease that is actively recruiting participants, run by Amydis. The registered enrollment target is 25 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06514001, a Phase 2 study of Alzheimer Disease, is actively recruiting participants, sponsored by Amydis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG AMDX-2011P
Study Locations (1)
Arizona
- Associated Retina Consultants - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06514001
The ClinicalTrials.gov registry entry for NCT06514001 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Amydis, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which AMDX-2011P is the first listed.
NCT06514001 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06514001 about?
NCT06514001 is a clinical study titled "A Study of AMDX-2011P in Participants With Alzheimer's Disease". The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
What is the current status of trial NCT06514001?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-03-07. Estimated completion is 2026-10.
What conditions does trial NCT06514001 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT06514001?
The interventions under investigation include: AMDX-2011P (DRUG).
Who is sponsoring clinical trial NCT06514001?
This trial is sponsored by Amydis, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514001 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.